Detalles de la búsqueda
1.
Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients.
Haemophilia
; 29(4): 1005-1012, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37335546
2.
Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
Eur J Haematol
; 111(4): 544-552, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37439123
3.
Efficacy and safety of fibrinogen concentrate for perioperative prophylaxis of bleeding in adult, adolescent, and pediatric patients with congenital fibrinogen deficiency: FORMA-02 and FORMA-04 clinical trials.
Transfusion
; 62(9): 1871-1881, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35932202
4.
Analysis of fibrinogen concentrate pharmacokinetics and dosing for bleeds and surgery in adults, adolescents, and children with congenital afibrinogenaemia and hypofibrinogenaemia.
Haemophilia
; 28(6): 1022-1032, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35925493
5.
Efficacy and safety of fibrinogen concentrate for on-demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency.
Haemophilia
; 27(2): 283-292, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33326665
6.
Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.
Thromb Haemost
; 121(11): 1400-1408, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33581698
Resultados
1 -
6
de 6
1
Próxima >
>>